Fig. 1 · Structure

Documents & Downloads

Fluorouracil

Cat. No. A10042 CAS 51-21-8

DNA and RNA synthesis inhibitor

Fluorouracil (Adrucil) is a suicide inhibitor and works through irreversible inhibition of thymidylate synthase.

In Stock

Publications for Fluorouracil

2 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Adi Jacob Berger, .et al. , Nat Cancer, 2021, 2, 1055-1070 PMID: 35121883

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

5-Fluorouracil inhibited cellular thymidylate-synthase activity less potently than the separately tested nucleoside FdUrd in SW480 and HeLa cells. Uridine/UMP rescue of 5-FU cytotoxicity, together with weak rescue by thymidine-directed supplementation, supports an RNA-related contribution under these conditions. Cellular responses should not be reduced to a single universal mechanism. [1]

In cultured cancer cells, 5-FU treatment produced mature ribosomes containing 5-fluorouridine in their rRNA. HCT116 ribosomes contained a reported 7–14 5-FUrd molecules per ribosome after 24 h at 5–100 µM 5-FU. Gel-purified rRNA and ribosomal-subunit controls supported the rRNA assignment. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Thymidylate synthase (Tumor cells)

Cellular Effect

Cell Line Activity Value Description Reference
143B IC50 13.01 μM Cytotoxicity against human 143B cells after 72 hrs by SRB assay [PMID: 27073055]
143B IC50 16.31 μM Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay [PMID: 27073055]
143B IC50 25.216 μM Antiproliferative activity against human 143B cells after 48 hrs by MTT assay [PMID: 29223717]
2008 IC50 4.2 μM Growth inhibition of human 2008 cells by crystal violet assay [PMID: 23075414]
4T1 IC50 23 μM Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay [PMID: 27496212]
4T1 IC50 28.12 μM Anticancer activity against mouse 4T1 cells expressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 31509699]
786-0 IC50 > 10 μM Antiproliferative activity against human 786-0 cells assessed as inhibition of cell viability after 48 hrs by MTT reduction assay [PMID: 27295506]
786-0 GI50 0.72 μM Anticancer activity against human 786-0 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay [PMID: 35182815]
786-0 GI50 0.72 μM Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay [PMID: 23887055]
A2780 IC50 0.2 μg/mL Cytotoxicity against human A2780 after 24 hrs by MTT assay [PMID: 19338315]
A2780 IC50 0.65 μg/mL Cytotoxicity against human A2780 cells by MTT assay [PMID: 18205316]
A2780 IC50 14 μM Antiproliferative activity against human A2780 cells expressing p53 after 72 hrs by celltiter-glo assay [PMID: 20873740]
A2780 GI50 3.5 μM Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay [PMID: 21489802]
A2780 GI50 4.4 μM Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay [PMID: 19664930]
A2780 IC50 5 μM Cytotoxicity against human A2780 cells after 96 hrs by MTT assay [PMID: 16499317]
A2780 IC50 5.1 μM Growth inhibition of human A2780 cells by crystal violet assay [PMID: 23075414]
A2780 IC50 5.4 μM Cytotoxicity against human A2780 cells by MTT method [PMID: 23164710]
A2780 IC50 7.21 μM Antiproliferative activity against human A2780 cells expressing p53 gene after 72 hrs by proliferative assay [PMID: 18469809]
A-375 IC50 21.09 μM Anticancer activity against human A375 cells expressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 31509699]
A-375 IC50 3.52 μM Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay [PMID: 36331508]

20 records · Scroll to view more

Fluorouracil Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Fluorouracil from 3 published references. In vitro models include SW480 colon adenocarcinoma and HeLa S3 cervical adenocarcinoma cells; SW480 and HeLa S3 cells.

Fluorouracil In Vitro Studies

5-FU did not uniformly suppress translation in HCT116 cells. At 10 or 50 µM for 24–48 h, IGF-1R mRNA association with heavy polysomes was maintained while actin/GAPDH association decreased. IGF-1R protein abundance also increased after 10 µM exposure. These findings show a selective cellular response during treatment rather than complete loss of translational capacity. [2]

Cellular thymidylate-synthase activity under fluoropyrimidine exposure

Cell-based study · SW480 colon adenocarcinoma and HeLa S3 cervical adenocarcinoma cells [1]

5-FU inhibited cellular TS activity less potently than FdUrd or FUrd under the same assay conditions. This is a cellular activity assay, not direct binding or a purified-enzyme potency measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative inhibition of cellular TS activityqualitative potency ordering FdUrd > FUrd > FU[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration series shown in Figure 6B; individual treatment points not transcribed
Exposure duration
1 h drug pretreatment followed by 90 min tracer incubation
Method
Cellular TS activity measured by release of tritiated water from [5-3H]deoxyuridine, relative to untreated cells
Reported limits
Vehicle and full numerical dose series are not specified in the extracted record; no exact IC50 is assigned.
Methods and source locations

Compound reported in the paper: 5-Fluorouracil; Compound label in the paper: FU

Molecular 5-FU evidence; no equivalence of supplier formulation, excipients, purity or Adooq lots is established.

Figure 6B; Methods: TS assay; Results final subsection

Relative inhibition of cellular TS activity: Radiotracer TS assay; activity normalized to untreated samples — Figure 6B; Results final subsection

Nucleoside and nucleotide rescue of 5-FU cytotoxicity

Cell-based study · SW480 and HeLa S3 cells [1]

Uridine and UMP partially reversed 5-FU-associated loss of MTT signal, whereas deoxyuridine and thymidine did not reverse it. dTMP gave a limited rescue only at much higher concentrations than UMP. The response differed from FdUrd and supports an RNA-related component under these conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Rescue of 5-FU-associated cytotoxicityqualitative response Partial reversal by Urd/UMP; no reversal by dUrd/dThd; limited dTMP reversal at concentrations reported as ~100- to 1000-fold higher than UMP[1]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 6D: FU 15 µM (SW480) or 50 µM (HeLa); Figure 6E: FU 50 µM in both lines; increasing rescue-agent concentrations shown in the panels
Exposure duration
Four days, concurrent drug and rescue-agent exposure
Method
MTT survival assay compared with untreated cells
Co-treatment
Concurrent uridine, deoxyuridine or thymidine (6D), or UMP, dUMP or dTMP (6E). FdUrd and FUrd are separately tested comparator drugs.
Reported limits
Vehicle and individual rescue-agent dose points are not transcribed; no absolute survival percentage or rescue EC50 is assigned.
Methods and source locations

Compound reported in the paper: 5-Fluorouracil; Compound label in the paper: FU

Molecular 5-FU evidence; no equivalence of supplier formulation, excipients, purity or Adooq lots is established.

Figure 6D-E; Results final subsection; Methods: Survival assays after drug exposure

Rescue of 5-FU-associated cytotoxicity: MTT after four days; survival data reported as mean ± SD of at least two parallel measurements — Figure 6D-E and caption; Results final subsection

5-FU incorporation into mature ribosomal RNA

Cell-based study · HCT116 concentration series; HCT116, HT29, SW480, ISRECO-1, MDA-MB-231, BT20, Panc1 and MiaPaCa cellular panel [2]

LC-HRMS detected 5-fluorouridine in mature ribosomal RNA after 5-FU exposure. Gel-purified rRNA and ribosomal-subunit purification controls support assignment to rRNA rather than contaminating nonribosomal RNA.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
5-FUrd content of HCT116 ribosomesreported range per ribosome 7–14 5-FUrd molecules per ribosome after 24 h at 5–100 µM 5-FU[2]
5-FUrd in rRNA across tested cell linesqualitative detection Detected in each tested cell line after 24 h at 10 µM 5-FU[2]

Literature-Reported Treatment Conditions

Treatment concentration
HCT116: 5–100 µM 5-FU; cellular panel: 10 µM 5-FU
Exposure duration
24 h
Method
LC-HRMS measurement of 5-FUrd in purified ribosomal RNA; untreated controls
Vehicle
Stock diluted in DMEM
Reported limits
Clinical stock formulation/excipients and product catalogue number are not specified in the cited Methods. Exact bar values are not estimated.
Methods and source locations

Compound reported in the paper: 5-Fluorouracil; Compound label in the paper: 5-FU

Molecular 5-FU evidence; no equivalence of supplier formulation, excipients, purity or Adooq lots is established.

Figure 2b-c; Supplementary Figure 3a-c; Results: 5-FU incorporates into ribosomes; relevant purification and LC-HRMS Methods

5-FUrd content of HCT116 ribosomes: LC-HRMS; main Figure 2b: mean ± SD of independent experiments, n = 3; range is stated in Results, not digitized — Figure 2b and Results: 5-FU incorporates into ribosomes

5-FUrd in rRNA across tested cell lines: LC-HRMS; Figure 2c mean ± SD, n = 3 independent experiments; gel purification controls n = 3; subunit-purification comparison n = 2 — Figure 2c and caption; Supplementary Figure 3a-c

Maintenance of IGF-1R translation during 5-FU treatment

Cell-based study · HCT116 colorectal cancer cells [2]

IGF-1R mRNA association with heavy polysomes was maintained while actin and GAPDH association decreased. IGF-1R protein abundance increased relative to untreated samples. These observations limit any claim that 5-FU uniformly blocks translation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Heavy-polysome/cytoplasmic mRNA ratioqualitative selective maintenance IGF-1R maintained; actin/GAPDH reduced under 5-FU treatment[2]
IGF-1R protein abundance relative to untreated cellsqualitative increase IGF-1R increased at 24 and 48 h; housekeeping protein levels were relatively stable[2]

Literature-Reported Treatment Conditions

Treatment concentration
Polysome/qPCR: 10 or 50 µM 5-FU; protein immunoblot: 10 µM 5-FU
Exposure duration
24 or 48 h
Method
Heavy-polysome versus cytoplasmic mRNA quantification; immunoblot using equivalent cell numbers and untreated controls
Vehicle
Stock diluted in DMEM
Reported limits
No exact effect size is inferred from bars. Protein analysis has only n = 2 independent experiments.
Methods and source locations

Compound reported in the paper: 5-Fluorouracil; Compound label in the paper: 5-FU

Molecular 5-FU evidence; no equivalence of supplier formulation, excipients, purity or Adooq lots is established.

Figure 4a-c; Supplementary Figure 6; Results: IGF-1R promotes 5-FU drug tolerance; Methods: Preparation of mRNA-associated polysomes; Quantitative RT-PCR; Western Blot

Heavy-polysome/cytoplasmic mRNA ratio: qRT-PCR of fractions; n = 3 independent experiments, biological samples measured in duplicate, mean ± SD — Figure 4a and caption; Supplementary Figure 6

IGF-1R protein abundance relative to untreated cells: Western blot; equivalent cell numbers loaded; mean ± SD of n = 2 independent experiments — Figure 4b-c and caption

Fluorouracil In Vivo Studies

In HCT116 xenografts in BALB/c scid mice, 5-FU at 40 µg/g intraperitoneally every two days for 14 days gave 50.7 ± 4.8% tumor-growth inhibition versus vehicle. Adding XMD8-92 at 50 µg/g increased inhibition to 69.8 ± 4.8% (mean ± SEM; n = 6 per group; p < 0.05 versus 5-FU alone). This is a model-specific combination result; XMD8-92 off-target effects were acknowledged by the authors. [3]

5-FU alone and with XMD8-92 in HCT116 xenografts

Animal study · 6- to 8-week-old BALB/c scid mice with subcutaneous HCT116 xenografts; randomized at ~150 mm³; n = 6 per group [3]

5-FU and XMD8-92 each inhibited tumor growth versus vehicle; their combination produced greater inhibition than 5-FU alone in this model. The combination result is not a single-agent 5-FU effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Day-14 tumor growth inhibition versus vehicle% TGI 50.7 ± 4.8%; p < 0.001 versus vehicle[3]
Day-14 tumor growth inhibition for combination versus vehicle% TGI 69.8 ± 4.8%; p < 0.001 versus vehicle; combination versus 5-FU alone p < 0.05[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every two days
Treatment course
14 days
Vehicle
Vehicle control: 30% hydroxypropyl-β-cyclodextrin
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlVehicle group; 5-FU-only arm additionally compared with combinationReference group for relative tumor growth and TGI[3]
XMD8-92 alone
XMD8-92 50 µg/g
Vehicle group; 5-FU-only arm additionally compared with combination45.9 ± 5.4% TGI; p < 0.001 versus vehicle[3]
5-FU alone
5-FU 40 µg/g
Vehicle group; 5-FU-only arm additionally compared with combination50.7 ± 4.8% TGI; p < 0.001 versus vehicle[3]
5-FU + XMD8-92
5-FU 40 µg/g + XMD8-92 50 µg/g
Vehicle group; 5-FU-only arm additionally compared with combination69.8 ± 4.8% TGI; p < 0.001 versus vehicle; p < 0.05 versus 5-FU alone[3]
Vehicle control
Model: 6- to 8-week-old BALB/c scid mice with subcutaneous HCT116 xenografts; randomized at ~150 mm³; n = 6 per group
Reported limits: Sex not specified in cited Methods; drug-arm vehicle composition is not separately detailed.
XMD8-92 alone
Model: 6- to 8-week-old BALB/c scid mice with subcutaneous HCT116 xenografts; randomized at ~150 mm³; n = 6 per group
Reported limits: Sex not specified in cited Methods; drug-arm vehicle composition is not separately detailed.
5-FU alone
Model: 6- to 8-week-old BALB/c scid mice with subcutaneous HCT116 xenografts; randomized at ~150 mm³; n = 6 per group
Reported limits: Sex not specified in cited Methods; drug-arm vehicle composition is not separately detailed.
5-FU + XMD8-92
Model: 6- to 8-week-old BALB/c scid mice with subcutaneous HCT116 xenografts; randomized at ~150 mm³; n = 6 per group
Reported limits: Sex not specified in cited Methods; drug-arm vehicle composition is not separately detailed.
Methods and source locations

Compound reported in the paper: 5-Fluorouracil; Compound label in the paper: 5-FU

Molecular 5-FU evidence; no equivalence of supplier formulation, excipients, purity or Adooq lots is established.

Figure 8A and embedded table; Results: ERK5 inhibition enhances 5-FU antitumor activity in vivo; Methods: Tumor xenograft mouse model; Statistical analysis

Day-14 tumor growth inhibition versus vehicle: TGI = 100 − (mean treated relative tumor volume / mean control relative tumor volume × 100); mean ± SEM, n = 6 mice/group — Figure 8A embedded table and caption

Day-14 tumor growth inhibition for combination versus vehicle: Same TGI calculation; mean ± SEM, n = 6 mice/group; two-tailed Student t-test reported — Figure 8A embedded table; Results in-vivo subsection

Vehicle control · Figure 8A table and caption; Methods: Tumor xenograft mouse model

XMD8-92 alone · Figure 8A table and caption; Methods: Tumor xenograft mouse model

5-FU alone · Figure 8A table and caption; Methods: Tumor xenograft mouse model

5-FU + XMD8-92 · Figure 8A table and caption; Methods: Tumor xenograft mouse model

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 51-21-8
Applications DNA and RNA synthesis inhibitor
Formula C4H3FN2O2
Molecular Weight 130.1
Synonyms Adrucil; 5-FU; Carac; Efudex; Fluoroplex
SMILES
C1=C(C(=O)NC(=O)N1)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 22 mg/mL (169.12 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
saline (warming)

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Fluorouracil Research References

  1. [1] Pettersen HS, Visnes T, Vågbø CB, et al. UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation Nucleic acids research (2011). PMID: 21745813 DOI: 10.1093/nar/gkr563 Source material
  2. [2] Therizols G, Bash-Imam Z, Panthu B, et al. Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance Nature communications (2022). PMID: 35013311 DOI: 10.1038/s41467-021-27847-8 Source material
  3. [3] Pereira DM, Simões AE, Gomes SE, et al. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism Oncotarget (2016). PMID: 27144434 DOI: 10.18632/oncotarget.9107 Source material

Publications

2 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Adi Jacob Berger, .et al. , Nat Cancer, 2021, 2, 1055-1070 PMID: 35121883

Added to your cart

View Cart Checkout
Loading...